Project LIPICARE - Combining nanotechnology, gene editing and CAR-T to create a 'one-shot' cure for cancer

LIPICARE 项目 - 结合纳米技术、基因编辑和 CAR-T 创造一种“一次性”治愈癌症的方法

基本信息

批准号：
10034471
负责人：
金额：
$ 153.66万
依托单位：
NANOVATION THERAPEUTICS UK LTD
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10034471
关键词：
Project LIPICARE Combining nanotechnology gene

项目摘要

LIPICARE is a bold and ambitious project conceived by a consortium of the UK's leading scientists in the field of gene and cancer therapy. We aim to combine advances in nanotechnology, cell therapy and gene editing to create a one-shot cure for cancer.Chimeric Antigen Receptor -- T cell (CAR-T) cancer immunotherapy involves genetically manipulating immune cells to attack cancers and represents a global market worth 20 billion dollars. Approved CAR-T products are all ex vivo therapies involving the complex and expensive process of manipulating cells in a lab and re-introducing them into a patient. One challenge, above all else, has prevented widespread adoption of this revolutionary technology, namely the inability to deliver therapeutic nucleic acids safely and effectively to the specific cells in the body.The COVID 19 pandemic has emphatically shown the lipid nanoparticle (LNP) mRNA delivery platforms are safe and effective in humans. Moreover, these LNP-mRNA vaccines can be manufactured for as little as £15 a dose. The next step is to guide these gene delivery technologies to specific cells in the body. This project will break down this current delivery barrier by creating T-cell specific LNP-nucleic acid delivery technologies to create CAR-T cells in vivo resulting in a cost-effective, accessible treatment for cancer -- Project LIPICARE.

Lipicare是一个由英国主要科学家在基因和癌症治疗领域的联盟构想的大胆而雄心勃勃的项目。我们的目的是结合纳米技术，细胞疗法和基因编辑的进步，以创建对癌症的单一治疗。Chimeric抗原受体-T细胞（CAR-T）癌症免疫疗法涉及遗传操纵免疫细胞以攻击癌症，并代表一个价值2000亿美元的全球市场。批准的CAR-T产品都是实体疗法，涉及在实验室中操纵细胞并将其重新引入患者的复杂且昂贵的过程。最重要的是，一项挑战阻止了这种革命性技术的宽度采用，即无法安全有效地向人体中的特定细胞提供热核酸。COVID19大流行强调显示了脂质纳米粒子（LNP）mRNA递送平台在人类中是安全有效的。此外，这些LNP-MRNA疫苗的生产只需每剂15英镑。下一步是将这些基因递送技术引导到体内特定细胞。该项目将通过创建T细胞特异性LNP-核酸递送技术来打破当前的递送障碍，以在体内创建CAR-T细胞，从而对癌症进行成本效益，易于访问的治疗方法-Lipicare Project lipicare。